QURE uniQure N.V.

NASDAQ
$38.23

uniQure N.V. (QURE) is expected to report earnings on November 4, 2026, before the market open. The consensus earnings estimate is a loss of $0.84 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +0.6% since its last earnings release on July 29, 2026.

uniQure N.V. Missed Consensus Estimates
Wednesday, July 29, 2026 · 7:05 AM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 4
Wednesday · 7:05 AM ET
Earnings Whisper
-
vs ($0.84)
Rev est $7.15M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $45.46

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About uniQure N.V.

uniQure NV is engaged in the field of gene therapy and have developed a gene therapy product to receive regulatory approval in the European Union.

Sector

Healthcare

Industry

Biotechnology

Charts powered in part by Lightweight Charts™ by TradingView.